US007981419B2 (12) United States Patent (10) Patent No.: US 7,981,419 B2 Yamashita et al. (45) Date of Patent: Jul. 19, 2011 (54) METHOD FOR TREATING EP 0314161 A1 10/1988 HYPOPHOSPHATEMICUSING FGF-23 ANTIBODY BONE DISEASES g;JP 561478926 :1 11/1986 JP H-02-117920 2/1990 (75) Inventors: Takeyoshi Yamashita, Tokyo (JP); W0 WO 99/60017 11/1999 TakashiSatoru Mizutani, Shimada, Yokohama Brookline, (JP); MA Seiji(US); $8W0 $8WO 00/73454 AlA1 120000 Fukumoto, Tokyo (JP) W0 WO 01/40466 A2 6/2001 W0 WO 01/42451 A2 6/2001 (73) Assignee: KyoWa Hakko Kirin Co., Ltd., Tokyo W0 WO 01/49740 A1 7/2001 (JP) W0 WO 01/60850 A1 8/2001 W0 WO 01/61007 A2 8/2001 ( * ) Notice: patentSubject' 1s to extendedany disclaimer, or adjusted the term under of this 35 W0 WO 02/08271 A1 1/2002 U.S.C. 154(1)) by 173 days. W0 WO 02/14504 A1 2/2002 W0 WO 02/76467 A1 3/2002 . W0 W0 02/088358 A2 11/2002 (21) Appl' No" 1262551 W0 W0 03/057733 A1 1/2003 . W0 WO 02/43478 5/2004 (22) Flledi Dec-1, 2008 W0 WO 2006/078072 A1 7/2006 WO WO-2008/057683 A2 5/2008 (65) Prior Publication Data W0 WO 2008/092019 A1 7/2008 US 2009/0110677 A1 Apr. 30, 2009 OTHER PUBLICATIONS Notice of Allowance for Korean Patent Application 10-2003 Related US. Application Data 7001931 Dated Nov. 26, 2008. (63) Continuation of application No. 10/344,339, ?led as Kenneth E. White et al., “Molecular cloning of a novel human UDP application No. PCT/JP01/06944 on Aug. 10, 2001, GaINAczpolypeptide N-acetylgalactosaminyltransferase, GaINAc T8, and analysis as a candidate autosomal dominant noW abandoned. hypophophatemic rickets (ADHR) gene”, Gene 246 (2000), 347 356. (30) Foreign Application Priority Data NCBI GenBank Accession No. NPi065689 (Mar. 25, 2007). NCBI GenBank Accession No. NMi020638 (Mar. 25, 2007). Aug. 11, 2000 (JP) ............................... .. 2000-245144 NCBI GenBank Accession No. AY566236 (Mar. 16, 2004). Sep. 21, 2000 2000-287684 Non-Final Of?ce Action dated Dec. 29,2009, issued in related U.S. Dec. 22, 2000 (JP) ............................... .. 2000-391077 Appl. No. 10/500,296. Apr. 19,2001 (JP) ............................... .. 2001-121527 International Search Report of PCT Patent Application No. PCT/ J P03/ 000 17 dated Feb. 5, 2003iinternational, counterpart to related (51) Int. Cl. U.S.App1. No. 10/500,296. A61K 39/395 (2006.01) International Search Report of PCT Patent Application No. PCT/ JP2008/052918 dated Mar. 13, 2008iinternationa1, counterpart to C07K 16/22 (2006.01) related U.S. Appl. No. l2/030,593. (52) US. Cl. ................................ .. 424/1391; 530/3879 Preissner et al., “Evaluation of the Immutopics Human FGF-23 (58) Field of Classi?cation Search ...................... .. None (C-term) ELISA Kit”, Clinical Chemistry, vol. 52, No. 6, Suppl. S, See application ?le for complete search history. Jun. 2006, p. A174. Supplementary European Search Report EP 08 71 1707 dated Feb. 9, (56) References Cited 2010. Japanese Of?ce Action Application No. JP 2003-558047 dated Jan. U.S. PATENT DOCUMENTS 26, 2010. Takashi Shimada et al., “Possible Roles of Fibroblast Growth Factor 5,585,089 A 12/1996 Queen et a1. 23 in Developing X-Linked Hypophosphatemia”, Clin. Pediatr. 5,958,879 A 9/1999 Kopchick et al. Endocrinol. 2005; 14(Suppl23) 33-37. 6,001,358 A 12/1999 Black et a1. 6,617,118 B2 9/2003 Ro?ler et a1. 7,094,551 B2 8/2006 Zahradnik et a1. (Continued) 7,223,563 B2 5/2007 Econs et al. 7,314,618 B2 l/2008 Econs et al. Primary Examiner * Christine J Saoud 2002/0156001 A1 10/2002 Econs et al. (74) Attorney, Agent, or Firm * Stephen A. Bent; Foley & 2004/0082506 A1 4/2004 Yamashita et a1. Lardner LLP 2004/0171825 A1 9/ 2004 Bougueleret et al. 2005/0048058 A1 3/2005 YamaZaki et al. 2006/0160181 A1 7/ 2006 Luethy et al. (57) ABSTRACT 2009/0110677 A1 4/2009 Yamashita et a1. A method for treating a hypophosphatemic bone disease, 2009/0148461 A1 6/2009 Yamazaki et a1. such as X-linked hypophosphatemia (XLH). The method FOREIGN PATENT DOCUMENTS entails administering to a subject a pharmaceutical composi CA 2418215 l/2002 tion, Which contains an antibody that binds to an FGF-23 CN 1446227 A 10/2003 polypeptide and a pharmaceutically acceptable carrier. EP 120694 10/1984 EP 125023 ll/l984 1 Claim, 37 Drawing Sheets US 7,981,419 B2 Page 2 OTHER PUBLICATIONS Fishwild, et al., “High-avidity Human IgGK Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” NatBiotechnol., Satoshi Toyoshima, “Experiment Techniques II”, Hirokawa Publish Jul. 1996, vol. 14, No. 7, pp. 845-851. ing Co., 1995, ?rst edition, pp. 110-113. Fukagawa, et al., “FGF23: its Role in Renal Bone Disease”, Pediat. Non-Final Of?ce Action U.S. Appl. No. 12/030,593 dated Apr. 6, Nephrol, 2006, vol. 21, pp. 1802-1806. 2010. Goding, J. W., Monoclonal Antibodies.‘ Principles and Practice, Marc DreZner, Reviews in Endocrine & Metabolic Disorders 2001;2: Academic Press, 1993 and 1995. 175 -186. Gupta, et al., “FGF-23 is Elevated by Chronic Hyperphosphatemia,” RaZZaque et al., Nephrol Dial Transplant, Oct. 2005; 20(10):2032 .I. Clin. Endocrinol.& Metab., 2004. vol. 89, No. 9, pp. 4489-4492. 2035. Imel, et al., “FGF23 Concentrations Vary with Disease Status in Inaba et al., Osteoporos Int. Oct. 2006; 17(10): 1506-1513. Autosomal Dominant Hypophosphatemic Rickets,” .I.of Bone and Vajdos et al., J. Mol. Biol. Jul. 5, 2002; 320(2):415-428. Mineral Research, 2007, vol. 22, pp. 520-526. Webster’s New World Dictionary, Third College Edition, 1988, pp. Ishida & Lonberg, IBC’s 11th Antibody Engineering, Abstract 2000. Jonsson, et al., “Fibroblast Growth Factor 23 in Oncogenic 1067-1068. Osteomalacia and X-Linked Hypophosphatemia,” N. Engl. .I. Med., Kobayashi et al., Eur J. Endocrinol. Jan. 2006;154(1)93-99. Apr. 24, 2003, vol. 348, No. 17, pp. 1656-1663. Canadian Patent Of?ce Action for 2,418,802 dated Feb. 13, 2009. Karlsson, et al., “Kinetic Analysis of Monoclonal Antibody-Antigen First Of?ce Action Chinese Application No. 2008100866831 dated Interactions with a New Biosensor Based Analytical System,” Jour Mar. 8, 2010. nal ofImmunological Methods, 1991, vol. 145, pp. 229-240. Human Fibroblast Growth Factor-23 (FGF-23) Elisa Kit 96-Well Kearney, et al., “A New Mouce Myeloma Cell Line that has Lost Plate, EZHFG23-32K, Millipore, Feb. 3, 2009 (17 pgs.). Immunoglobulin Expression but Permits the Construction of Anti Human Intact FGF-23 Elisa Kit, Enzyme-Linked ImmunoSorbent body-Secreting Hybrid Cell Lines”, J Immunology, Sep. 1979, vol. Assay (ELISA) for the Determination of Human Fibroblas Growth 123, No. 3, pp. 1548-1550. Factor 23 Levels in Plasma or Cell Culture, 96 Test Kit, Cat. No. King, D.J., Applications and Engineering ofMonoclonal Antibodies, 60-6500, Immotopics, Inc., Oct. 2008 (4 pgs.). T. J. International Ltd, 1998. Monoclonal Anti-human FGF-23 Antibody, R&D Systems. Cat. No. Kitamura, et al., “A B Cell-de?cient Mouse by Targeted Distribution MAB2604, Apr. 18, 2005. of the Membrane Exon of the Immunoglobulin u Chain Gene,” Monoclanal Anti-human/mouse FGF-23 Antibody, R&D Systems, Nature, 1991, vol. 350, No. 4, pp. 423-426. Cat. No. MAB2629, Sep. 13, 2007. Kohler, et al., “Derivation of Speci?c Antibody-producing Tissue Monoclonal Anti-mouse FGF-23 Antibody, R&D Systems, Cat. No. Culture and Tumor Lines by Cell Fusion”, European .I. Immunology, MAB26291, Mar. 20, 2007. 1966, vol. 6, pp. 511-519. Final Of?ce Action for US. Appl. No. 10/500,296 dated Apr. 10, Lah, et al., “Phage Surface Presentation and Secretion of Antibody Fragments using an Adaptable Phagemid Vector,” Human Antibodies 2009. &Hybridomas, 1994, vol. 5, Nos. 1 and 2, pp. 48-56. Non-Final Of?ce Action for US. Appl. No. 10/500,296 dated Jul. 24, Larsson, et al., “Circulating Concentration of FGF-23 Increases as 2008. Renal Function Declines in Patients with Chronic Kidney Disease, Advisory Action for US. Appl. No. 10/500,296 dated Mar. 28, 2008. but does not Change in Response to Variation in Phosphate Intake in Final Of?ce Action for US. Appl. No. 10/500,296 dated Oct. 19, Healthy Voluneers,” Kidney International, 2003, vol. 64, pp. 2272 2007. 2279. Non-Final Of?ceAction for US. Appl. No. 10/500,296 dated Jan. 30, LorenZ-Depiereux, et al., The Autosomal Dominant 2007. Hypophosphatemic Rickets (ADHR) Gene is a Secreted Fibroblast Non-Final Of?ceAction for US. Appl. No. 10/500,296 dated Jan. 13, Growth Factor (FGF23), Eur .I. Human Genetics, 2001, vol. 9, 2006. Supplement 1, P0772, 10’h International Congress of Human Genet Aono et al., “The improving effect of anti FGF23 neutralizing anti ics, Vienna Austria, May 15-19, 2001. body on hypophosphatemia and rickets of Hyp mice”, The Japanese LorenZ-Depiereux, et al., “DMPl Mutations in Auto somal Recessive Society forBone and Mineral Research (.ISBMR), Annual Meeting of Hypophosphatemia Implicate a Bone Matrix Protein in the Regula the JSBMR, 22” Program, Aug. 2004, vol. 22, pp. 137. (English tion of Phosphate Homeostasis,”Nature Genetics, Nov. 2006, vol. 38, translation provided). No. 11, pp. 1248-1250. Ando, et al., Tan-Clone-Kotai-Jikken-Manual (“Experimental Mark, et al., “Site-speci?c Mutagenesis of the Human Fibroblast Manual for Monoclonal Antibody”) (written by and published by Interferon Gene”, Proc NatlAcad Sci U.S.A., Sep. 1984, vol. 81, No. Kodansha Scienti?c, Ltd., Tokyo, Japan (1991). 18, pp. 5662-5666. Antibody Engineering, A Practical Approach, IRL Press, 1996.